Pilot description
Pilot start-date: July, 2020
Objective: The European Commission is worked together with Member States, the European Blood Alliance (EBA), the European Centre for Disease Prevention and Control (ECDC) and other health professionals to support a study of convalescent plasma as a treatment for COVID-19 patients. The study assessed in which conditions the convalescent plasma treatment was most effective, in order to take data-driven decisions on the therapy and focus the efforts of the research in the most promising directions.
The open-access database gathers and makes available data on convalescent plasma donations and patient outcomes following transfusions. It includes data from blood establishments regarding convalescent donors, plasma collection, and plasma components, as well as from clinical trials and from wider monitored use and consolidates EU evidence on the safety and effectiveness of this therapy.
The database has been developed by the European Commission (DG SANTE, DG DIGIT, and DG CNECT) in collaboration with EBA and is managed jointly by EBA and the European Commission.
Addressed use cases:
- Text analysis
- Web analysis
- Descriptive analysis
- Advanced data visualisation
Data used: Plasma collection data, clinical use data and clinical trial data
Data sources:
- Safety and clinical outcomes data (Anonymised)
- Patient-level donor data input by blood establishments (Anonymised)
Stakeholders
The European Commission (DG SANTE) together with Member States
European Blood Alliance (EBA)